SPX3,911.74+116.01 3.06%
DIA315.02+8.28 2.70%
IXIC11,607.62+375.43 3.34%

BRIEF-Alnylam Reports Results From Phase 2 Study Of IgA Nephropathy Treatment

reuters.com · 06/09/2022 07:07
BRIEF-Alnylam Reports Results From Phase 2 Study Of IgA Nephropathy Treatment

- Alnylam Pharmaceuticals Inc ALNY:

  • ALNYLAM REPORTS POSITIVE TOPLINE RESULTS FROM PHASE 2 STUDY OF INVESTIGATIONAL CEMDISIRAN FOR THE TREATMENT OF IGA NEPHROPATHY

  • ALNYLAM PHARMACEUTICALS - CEMDISIRAN TREATMENT RESULTED IN A 37% MEAN REDUCTION IN 24-HOUR URINE PROTEIN TO CREATININE RATIO, RELATIVE TO PLACEBO

  • ALNYLAM PHARMACEUTICALS INC - CEMDISIRAN SHOWED ACCEPTABLE SAFETY PROFILE, SUPPORTING CONTINUED CLINICAL DEVELOPMENT

  • ALNYLAM PHARMACEUTICALS INC - RESULTS OF SECONDARY ENDPOINTS WERE ALSO CONSISTENT WITH A THERAPEUTIC BENEFIT OF CEMDISIRAN IN IGAN

  • ALNYLAM PHARMACEUTICALS INC - THERE WERE NO SIGNIFICANT DRUG-RELATED SAFETY SIGNALS

Source text for Eikon: ID:nBw1Cyl5ba

Further company coverage: ALNY


((Reuters.Briefs@thomsonreuters.com;))